Based on the excellent results achieved during the 1st clinical trial, today EpiTech officially launched its 2nd clinical trial, a 40 patient, multi center, double masked, randomized controlled study.

This clinical trial is aligned with EpiTech’s regulatory strategy and is targeting severe aqueous deficient Dry eye patients for both eyes treatment with a 12 week follow-up period. Participating centers include Shaare Zedek Medical Center (Jerusalem), Ichilov MC (Tel-Aviv) and Wolfson MC (Holon).

Trial recruitment has already begun for all sites. If you are a severe Dry Eye Disease patient and wish to participate in this ongoing trial, please log into our page and our trial medical team will get back to you.